share_log

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $170

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $170

古根海姆維持對Neurocrine Biosciences的買入,將目標股價上調至170美元
Benzinga ·  05/02 14:23

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $164 to $170.

古根海姆分析師亞廷·蘇內哈維持Neurocrine Biosciences(納斯達克股票代碼:NBIX)的買入並將目標股價從164美元上調至170美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論